BioMarin Pharma

Forecast & Rating27 analysts currently cover BioMarin Pharma, with about 74.1% giving a positive rating — meaning they expect the stock to rise. The average price target is $91.62, about 58.5% upside from the current price of $57.82. Price targets range from $60.00 to $124.00 — a wide spread, showing clear disagreement over just how much BioMarin Pharma can rise. Historically, about 36.7% of past price targets were eventually met, which adds credibility. For you, this means most professionals who study BioMarin Pharma closely still see room for the stock to rise. Data as of Oct 2, 2026; for reference only and not investment advice.